

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

No

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

The committee can only appraise the technology within its marketing authorisation. The committee will consider all potential equality issues during the appraisal process.
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No

- | | |
|----|---|
| 4. | Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
|----|---|

No

Approved by Associate Director (name): ...Lorna Dunning

Date: 07/04/25